CL2017001941A1 - Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor - Google Patents
Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumorInfo
- Publication number
- CL2017001941A1 CL2017001941A1 CL2017001941A CL2017001941A CL2017001941A1 CL 2017001941 A1 CL2017001941 A1 CL 2017001941A1 CL 2017001941 A CL2017001941 A CL 2017001941A CL 2017001941 A CL2017001941 A CL 2017001941A CL 2017001941 A1 CL2017001941 A1 CL 2017001941A1
- Authority
- CL
- Chile
- Prior art keywords
- present
- icodextrin
- pharmaceutically acceptable
- mixture
- acceptable solution
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 229920002177 Icodextrin Polymers 0.000 abstract 5
- 229940016836 icodextrin Drugs 0.000 abstract 5
- 229920002472 Starch Polymers 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 235000019698 starch Nutrition 0.000 abstract 3
- 239000008107 starch Substances 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se refiere a una solución, en particular una solución farmacéuticamente aceptable, que comprende icodextrina e hidroxialquil almidón (HAS), en donde la icodextrina está presente a una concentración de 1 a 7.5% (p / v) y en donde dicha HAS está presente en una concentración de 1 a 15% (p / v). La presente invención se refiere además a la citada solución farmacéuticamente aceptable para uso como medicamento y para su uso en (por ejemplo, en métodos de) prevención de formación de metástasis y/o recaída por administración en una cavidad corporal de un sujeto afectado con cáncer. La presente invención se refiere además a un kit que comprende icodextrina y HAS en cantidades previamente pesadas y un medio farmacéuticamente aceptable para disolver las mismas, a un dispositivo que comprende una solución farmacéuticamente aceptable de la presente invención y medios para administrar la misma, así como a una solución farmacéuticamente aceptable que comprende icodextrina e hidroxialquil almidón a una concentración total en el rango de 1 a 20% (p / v), en donde la relación en peso de la icodextrina en relación con el hidroxialquil almidón está en el rango de 0.05: 1 a 5: 1, para su uso en la prevención de la formación de metástasis y/o recaída por administración en una cavidad corporal de un sujeto afectado con cáncer.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153178 | 2015-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001941A1 true CL2017001941A1 (es) | 2018-05-04 |
Family
ID=52469605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001941A CL2017001941A1 (es) | 2015-01-30 | 2017-07-28 | Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180021367A1 (es) |
| EP (1) | EP3250193B1 (es) |
| JP (1) | JP6347899B2 (es) |
| KR (1) | KR101899276B1 (es) |
| CN (2) | CN115969875A (es) |
| AU (1) | AU2016211128B2 (es) |
| BR (1) | BR112017014467A2 (es) |
| CA (1) | CA2974865C (es) |
| CL (1) | CL2017001941A1 (es) |
| EA (1) | EA034858B1 (es) |
| MX (1) | MX2017009733A (es) |
| WO (1) | WO2016120490A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176805A (zh) * | 2016-08-24 | 2016-12-07 | 华仁药业股份有限公司 | 一种妇科手术用防粘连冲洗液及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1248602A (en) * | 2000-11-03 | 2002-05-15 | Ml Lab Plc | Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| US20070155672A1 (en) * | 2006-01-05 | 2007-07-05 | Markus Voges | Sterilized peritoneal dialysis solutions containing heparin |
| CN101130087A (zh) * | 2007-08-14 | 2008-02-27 | 北京费森尤斯卡比医药有限公司 | 腹腔化疗用药物载体溶液及药物组合物 |
| EP2560663B1 (en) * | 2010-04-23 | 2016-06-22 | Baxter International Inc. | Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy |
| EP2591008A1 (en) * | 2010-07-09 | 2013-05-15 | Fresenius Kabi Deutschland GmbH | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| WO2013113765A1 (en) * | 2012-01-30 | 2013-08-08 | Fresenius Kabi Deutschland Gmbh | Hydroxyalkyl starch for the treatment of head and neck cancers by reduction of tumor growth rates |
-
2016
- 2016-02-01 EA EA201791713A patent/EA034858B1/ru not_active IP Right Cessation
- 2016-02-01 EP EP16702534.5A patent/EP3250193B1/en not_active Not-in-force
- 2016-02-01 CN CN202211003927.1A patent/CN115969875A/zh active Pending
- 2016-02-01 AU AU2016211128A patent/AU2016211128B2/en not_active Ceased
- 2016-02-01 BR BR112017014467A patent/BR112017014467A2/pt not_active Application Discontinuation
- 2016-02-01 CA CA2974865A patent/CA2974865C/en active Active
- 2016-02-01 KR KR1020177024432A patent/KR101899276B1/ko not_active Expired - Fee Related
- 2016-02-01 JP JP2017540058A patent/JP6347899B2/ja not_active Expired - Fee Related
- 2016-02-01 WO PCT/EP2016/052076 patent/WO2016120490A1/en not_active Ceased
- 2016-02-01 CN CN201680007721.2A patent/CN107206016A/zh active Pending
- 2016-02-01 US US15/547,283 patent/US20180021367A1/en not_active Abandoned
- 2016-02-01 MX MX2017009733A patent/MX2017009733A/es unknown
-
2017
- 2017-07-28 CL CL2017001941A patent/CL2017001941A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3250193B1 (en) | 2021-09-08 |
| JP2018503655A (ja) | 2018-02-08 |
| MX2017009733A (es) | 2018-04-10 |
| AU2016211128B2 (en) | 2018-01-04 |
| CN115969875A (zh) | 2023-04-18 |
| EA034858B1 (ru) | 2020-03-30 |
| CA2974865C (en) | 2018-11-06 |
| HK1247130A1 (zh) | 2018-09-21 |
| JP6347899B2 (ja) | 2018-06-27 |
| US20180021367A1 (en) | 2018-01-25 |
| WO2016120490A1 (en) | 2016-08-04 |
| KR101899276B1 (ko) | 2018-09-14 |
| KR20170105634A (ko) | 2017-09-19 |
| EP3250193A1 (en) | 2017-12-06 |
| CA2974865A1 (en) | 2016-08-04 |
| BR112017014467A2 (pt) | 2018-01-16 |
| CN107206016A (zh) | 2017-09-26 |
| AU2016211128A1 (en) | 2017-07-13 |
| EA201791713A1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| GT201700056A (es) | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
| EA201690388A1 (ru) | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов | |
| BR112015008954A2 (pt) | composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas | |
| CY1119391T1 (el) | Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
| AR104361A1 (es) | Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| EA201792516A1 (ru) | Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение |